4-氨基-1-[5-O-[羟基[[羟基(磷酰氧基)亚膦酰]氧基]亚膦酰]-beta-D-阿拉伯糖呋喃基]-2(1H)-嘧啶酮 | 13191-15-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 中文名称: 4-氨基-1-[5-O-[羟基[[羟基(磷酰氧基)亚膦酰]氧基]亚膦酰]-beta-D-阿拉伯糖呋喃基]-2(1H)-嘧啶酮
• 英文名称: 2'-aracytidine 5'-triphosphate
• 英文别名: araCTP；cytarabine triphosphate；cytosine arabinoside 5'-triphosphate；1-β-D-arabinofuranosylcytosine triphosphate；Arabinofuranosylcytosine triphosphate；[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• CAS: 13191-15-6
• 化学式: C₉H₁₆N₃O₁₄P₃
• 分子量: 483.159
• InChiKey: PCDQPRRSZKQHHS-CCXZUQQUSA-N

物化性质

• 沸点：
  849.2±75.0 °C(Predicted)
• 密度：
  2.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -5.6
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  268
• 氢给体数：
  7
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  5'-[N4-(allyloxycarbonyl)cytosine arabinosyl] benzyl N-methyl-N-(4-chlorobutyl) phosphoramidate 在 palladium/alumina 、 钯 氢气 、 tris(tetra-n-butylammonium) hydrogen pyrophosphate 、 sodium 4-methylbenzenesulfinate 、 三苯基膦 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 4-氨基-1-[5-O-[羟基[[羟基(磷酰氧基)亚膦酰]氧基]亚膦酰]-beta-D-阿拉伯糖呋喃基]-2(1H)-嘧啶酮
  参考文献：
  名称：

  从活化的核苷氨基磷酸酯制备三磷酸核苷的新方法。

  摘要：

  [反应：见正文]已经开发了一种制备三磷酸核苷的新方法。该策略使用高反应性的吡咯烷磷酰胺酸两性离子中间体，该中间体与三（四正丁基铵）焦磷酸氢进行有效偶联，生成核苷三磷酸。

  DOI：

  10.1021/ol049267j

文献信息

• METHOD OF DETECTING CANCER CELL ACQUIRING DRUG-RESISTANCE
  申请人：BML, Inc.

  公开号：EP1715041A1

  公开（公告）日：2006-10-25

  It is an object of the present invention to find out a novel gene marker by which a drug-resistant cancer cell can be detected and provide a means of efficiently and comprehensively detecting a drug-resistant cancer cell using this marker. In the present invention, gene amplifications or deletions have been analyzed in cancer cell strains resistant to drugs, which are anticancer drugs having particularly serious side effects and being administered to cancer patients at a high frequency (namely, camptothecins, cisplatins, etoposides, adriamycins (ADM), and cytosine arabinosides), and parent cancer cell strains. As a result, it was found out that the acquisition of drug-resistance to an anticancer drug in a test cancer cell can be detected by detecting amplification of one or more genes selected from ABC transporter genes and BCL2 family genes consisting of ABCA3 gene, ABCB6 gene, ABCB8 gene, ABCB10 gene, ABCC4 gene, ABCC9 gene, ABCD3 gene, ABCD4 gene, ABCE1 gene, ABCF2 gene, BCL2L2, BCL2L10, BCL2L1, and BCL2A1 which are novel gene markers relating to the acquisition of drug resistance of cancer cells.

  本发明的目的是找出一种新的基因标记，通过这种标记可以检测出耐药癌细胞，并提供一种利用这种标记有效而全面地检测耐药癌细胞的方法。本发明分析了耐药癌细胞株和母本癌细胞株的基因扩增或缺失情况，耐药癌细胞株是指副作用特别严重、癌症病人经常服用的抗癌药物（即喜树碱类、顺铂类、依托泊苷类、阿霉素类（ADM）和胞嘧啶阿拉伯糖苷类）。ABCB6 基因、ABCB8 基因、ABCB10 基因、ABCC4 基因、ABCC9 基因、ABCD3 基因、ABCD4 基因、ABCE1 基因、ABCF2 基因、BCL2L2 基因、BCL2L10 基因、BCL2L1 基因和 BCL2A1 基因，这些基因是与癌细胞获得抗药性有关的新型基因标记。
• Process for cognate nucleotide detection in a nucleic acid sequencing workflow
  申请人：Omniome, Inc.

  公开号：US10975427B2

  公开（公告）日：2021-04-13

  Method and composition for identifying cognate nucleotides in a Sequencing By Binding™ procedure, wherein one or more labeled nucleotides are detected in ternary complexes but never incorporated. Labeled nucleotides can be incorporable nucleotides that contact preformed blocked primed template nucleic acids. Alternatively, labeled nucleotides are labeled non-incorporable nucleotides. Labeled nucleotides, including labeled non-incorporable nucleotides, can be detected in ternary complexes in the same reaction mixture that incorporates a reversible terminator nucleotide to create a blocked primed template nucleic acid. Detection of ternary complexes can take place in the presence of a catalytic metal ion.

  在 Sequencing By Binding™ 程序中识别同源核苷酸的方法和组合物，其中在三元复合物中检测到一种或多种标记核苷酸，但从未与之结合。标记的核苷酸可以是可结合的核苷酸，与预先形成的阻断引物模板核酸接触。或者，标记的核苷酸是标记的不可结合核苷酸。标记的核苷酸，包括标记的不可结合核苷酸，可以在同一反应混合物中的三元复合物中检测到，该反应混合物结合了可逆的终止子核苷酸，生成了阻断引物的模板核酸。三元复合物的检测可在催化金属离子存在的情况下进行。
• NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS
  申请人：GeneForm Technologies Limited

  公开号：EP1594987B1

  公开（公告）日：2009-05-27
• Nucleic acid sequencing methods, kits and reagents
  申请人：Hoser J. Mark

  公开号：US20070148645A1

  公开（公告）日：2007-06-28

  The present invention relates to nucleic acid sequencing methods, kits and reagents, and more particularly to methods of sequencing nucleic acid which employ a nucleic acid processing enzyme and one or more nucleotide analogues that are capable of binding to the active site of the enzyme and to complementary bases in the nucleic acid molecule being sequenced, but which are non-incorporable or inhibitors of the nucleic acid processing enzyme. In further aspects, the present invention relates to conjugates which comprise a deoxyribonucleotide triphosphates (DNTPs) or an analogue thereof linked to an intercalating dye.
• Method of detecting cancer cell acquiring drug-resistance
  申请人：Inazawa Johji

  公开号：US20090143236A1

  公开（公告）日：2009-06-04

  It is an object of the present invention to find out a novel gene marker by which a drug-resistant cancer cell can be detected and provide a means of efficiently and comprehensively detecting a drug-resistant cancer cell using this marker. In the present invention, gene amplifications or deletions have been analyzed in cancer cell strains resistant to drugs, which are anticancer drugs having particularly serious side effects and being administered to cancer patients at a high frequency (namely, camptothecins, cisplatins, etoposides, adriamycins (ADM), and cytosine arabinosides), and parent cancer cell strains. As a result, it was found out that the acquisition of drug-resistance to an anticancer drug in a test cancer cell can be detected by detecting amplification of one or more genes selected from ABC transporter genes and BCL2 family genes consisting of ABCA3 gene, ABCB6 gene, ABCB8 gene, ABCB10 gene, ABCC4 gene, ABCC9 gene, ABCD3 gene, ABCD4 gene, ABCE1 gene, ABCF2 gene, BCL2L2, BCL2L10, BCL2L1, and BCL2A1 which are novel gene markers relating to the acquisition of drug resistance of cancer cells.